Abstract
Objectives:
To evaluate the quality of life (QOL) of patients with primary axillary hyperhidrosis treated with sofpironium bromide (sofpironium) using a newly developed combination of patient-reported outcomes (PROs) specific to axillary hyperhidrosis: Axillary Sweating Daily Diary (ASDD) which assess severity and impact of axillary hyperhidrosis, Weekly Impact (WI) Items, and Patient Global Impression of Change (PGIC).
Methods:
From March 2022 to October 2023, patients with primary axillary hyperhidrosis who were treated with sofpironium at our hospital were retrospectively investigated. We assessed the results of PRO evaluations using the ASDD, WI Items, and PGIC before and after treatment; hyperhidrosis disease severity scale (HDSS); and occurrence of adverse drug reactions.
Results:
The study included 31 patients with a median age of 40 years; 77.4% were female, and 77.4% were in their 30s and 50s. The proportion of patients with HDSS ≥ 3 decreased significantly from 96.8% to 41.9% before and after treatment. Meanwhile, regarding the ASDD, the mean score (mean±standard deviation) for the severity of axillary sweating significantly improved from 5.0±2.02 to 3.3±2.3; the proportion of patients who answered "moderate/great/extreme impact" of axillary sweating on their activities significantly decreased from 46.7% to 3.3%; and the proportion of patients reporting "moderate/very/extreme bothersomeness" of axillary sweating significantly decreased from 76.7% to 26.7%. For WI Items, the proportion of patients who responded that they were affected by axillary sweating significantly decreased in 5 out of 6 items. According to the PGIC, 93.5% of patients reported their axillary sweating status as "much better" to "a little better" compared to before treatment. No adverse drug reactions were reported during the study period.
Conclusion:
Sofpironium may not only improve the symptoms of primary axillary hyperhidrosis but also improve patient's QOL, thus reducing their disease burden.
